

The Prognostic Value of Circulating Tumor Cells in Patients with Melanoma: A Systematic Review and Meta-analysis

Simone Mocellin,^{1,2} Dave Hoon,³ Alessandro Ambrosi,⁴ Donato Nitti,¹ and Carlo Riccardo Rossi¹

Abstract **Background:** The detection of circulating tumor cells (CTC) in patients with melanoma represents an appealing prognostic tool, but no consensus exists on this topic. We aimed to comprehensively and quantitatively summarize the evidence for the use of CTC to predict patients' clinical outcome.

Methods: Fifty-three studies enrolling 5,433 patients were reviewed. Correlation of CTC status with tumor-node-metastasis disease stage and patients' overall (OS) and progression-free (PFS) survival was assessed by means of association statistics and meta-analysis, respectively.

Results: CTC status correlated with both tumor-node-metastasis stage (stage I, 32%; stage II, 41.7%; stage III, 41.1%; stage IV, 47.4%; $P_{\text{trend}} < 0.0001$) and survival (OS: hazard ratio, 2.42; 95% confidence interval, 1.7-3.45, $P < 0.0001$; PFS: hazard ratio, 2.45; 95% confidence interval, 1.78-3.38; $P < 0.0001$). However, statistical heterogeneity was significant for both OS and PFS, likely underscoring the wide variability in study design. Furthermore, CTC positivity rates in early stages were higher and in the metastatic setting were lower than expected, which indicates an unsatisfactory accuracy of currently available CTC detection assays.

Conclusions: Our findings suggest that CTC might have a clinically valuable prognostic power in patients with melanoma. However, the heterogeneity of the studies thus far published warrants caution not to overestimate the favorable results of pooled data.

The search for minimal residual disease in the peripheral blood is routinely done for the therapeutic management of patients with hematologic malignancies, as the bloodstream is the "physiologic" milieu for this kind of tumors. By contrast, the biological significance of circulating tumor cells (CTC) in solid tumors is still debated (1). The largest experience in this field has been gained in patients affected with melanoma, the first solid tumor recognized to shed CTC by PCR-based amplification of the melanocyte-specific tyrosinase gene (2). Although tens of studies have been done and thousands of patients have been enrolled, there is no consensus on CTC biological significance in patients with melanoma (as well as other solid malignancies) and thus on the use of CTC in the routine clinical setting. At this point, a question may arise

whether—based on the available findings—it is justified to further explore the prognostic power of CTC.

With the aim of gaining a better insight into the prognostic value of CTC in patients with melanoma, we undertook a systematic review of published studies and used standard meta-analysis techniques to pool together and quantitatively summarize the available evidence. We intended to assess the quality of published series, to identify technical factors influencing CTC detection rates, and to evaluate the effect of CTC status (presence versus absence) on both indirect [tumor-node-metastasis (TNM) stage] and direct [overall (OS) and progression-free (PFS) survival] indicators of patients' clinical outcome.

Materials and Methods

Search strategy, eligibility criteria, and data extraction. A systematic review of original articles analyzing the prognostic value of CTC in melanoma patients was done by searching Medline, Embase, Cancerlit, and Cochrane databases. The search strategy included the following keywords variably combined: "melanoma," "circulating tumor (melanoma) cells," "disseminated (melanoma) tumor cells," "minimal residual disease," "prognosis," "prognostic marker," "peripheral blood," "polymerase chain reaction," and "immunomagnetic cell enrichment." Original and review articles published until November 2005 were sought, considering the latter as an additional source of original works otherwise overlooked. When appropriate, cited references from selected articles were also reviewed. Only studies published in peer-reviewed journals were included; data from letters and meetings abstracts were not considered eligible. Authors were contacted whenever data not reported were useful to include the study into this systematic review or to rule out data published in different papers but regarding overlapping series.

Authors' Affiliations: ¹Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Padova; ²Istituto Oncologico Veneto, Padova, Italy; ³Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California; and ⁴Statistics Center for Biomedical Sciences, San Raffaele University, Milan, Italy

Received 4/4/06; revised 5/17/06; accepted 5/23/06.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Requests for reprints: Simone Mocellin, Clinica Chirurgica II Dipartimento di Scienze Oncologiche & Chirurgiche, Università di Padova, via Giustiniani 2, 35128 Padova, Italy. Phone: 39-049-8211851; Fax: 39-049-651891; E-mail: mocellins@hotmail.com.

©2006 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-06-0823

Studies were eligible if disease stage and/or survival (OS and/or PFS) data were reported in melanoma patients stratified by CTC status (presence/positive versus absence/negative). The major restriction criterion was the number of patients enrolled, which had to be ≥ 30 . Articles describing the detection of free RNA or DNA in plasma samples were not considered. Care was taken to account for overlapping and duplicate data sets. To this aim, we identified articles that included the same cohort of patients by reviewing between-study similarity, investigators, recruitment period, and inclusion criteria. When the same authors reported results obtained from the same series of patients in multiple publications, only the largest or the most informative (e.g., reporting survival data) were included in the analysis. Duplicate reports were included in the specific analyses only if they applied different methods, tumor markers, or disease stage, and if they added survival analysis previously not done. A cohort of patients was not included more than once in the same analysis.

A comprehensive database was designed to ensure that all data needed for analysis were publicly available (Supplementary Table S1). Data were extracted by two investigators (S.M. and C.R.R.) to ensure homogeneity of data collection and to rule out the effect of subjectivity in data gathering and entry. Disagreements were resolved by iteration, discussion, and consensus. To unravel potential systematic biases, a third investigator (D.N.) did a concordance study by independently reviewing 50% of the eligible studies randomly chosen: Complete concordance was reached for all variables assessed. All statistical analyses were done with the supervision of a biostatistician (A.A.).

Statistical analysis. Three main methods were used to summarize results: (a) weighted multiple regression was used to evaluate the influence of several factors (publication year, number of TNM stages considered in the study, enrollment of stage IV patients, *in vitro* sensitivity assay, blood sample volume, number of blood samples per patient, RNA extraction method, PCR technique, and number of tumor markers used to detect CTC) on CTC detection rates; the square root of the sample size was used as weighting factor, and the arcsin transformation of the CTC positivity rate of each study was considered the dependent variable; (b) to assess the association between CTC status and TNM stages, the Cochran-Armitage trend test was fitted to data pooled across studies; (c) standard meta-analysis methods (3, 4) were applied to evaluate the overall effect of CTC status on patients' survival.

The association between CTC and survival (OS and PFS) was derived as a weighted average of study-specific estimates of the hazard ratio [HR, (observed - expected cases)_{CTC pos} / (observed - expected cases)_{CTC neg}], using the inverse of variance as the weighting factor (3, 4). The natural logarithm of HR (lnHR) and the corresponding SE were used as data points for the meta-analysis. In studies evaluating the independence of CTC prognostic value by means of multivariate survival analysis (Cox proportional hazards regression model), HRs and confidence intervals (CI) are usually reported. For studies performing only univariate survival analysis (log-rank test-based comparison of Kaplan-Meier survival curves), HRs and 95% CIs were calculated from survival curves adopting a hierarchical series of steps as per Parmar et al. (5). Briefly, within a given study, survival probabilities for each group (CTC-positive and CTC-negative patients) were calculated for a minimum of six nonoverlapping time points. Then, the effective number of patients alive, at risk, and censored was calculated for each time point. The overall lnHR for each study was considered a weighted sum of the individual estimates of the lnHR during each time interval (*t*), where the weights are inversely proportional to the variance of each estimate (var), as described by the following expression:

$$\ln HR = \frac{\sum_{t=1}^T \frac{\ln HR(t)}{\text{var}[\ln HR(t)]}}{\sum_{t=1}^T \frac{1}{\text{var}[\ln HR(t)]}}$$

The corresponding SE was calculated according to the following formula: $1/\sqrt{V}$, where *V* is the variance of the log-rank statistic.

Because a mixture of log-rank and Cox model estimates were obtained from the eligible studies, results were combined using the generic inverse variance method (3, 4). Meta-analysis was first done using the fixed-effects model, which assumes that all the studies share the same common prognostic effect. Results (effect sizes) consistency among studies was investigated by means of two heterogeneity tests: the χ^2 -based Cochran's *Q* test and the *I*² statistic [$(Q - df) / Q \times 100$, where *Q* is the Cochran statistic and *df* are the degrees of freedom, that is the number of studies minus 1; it indicates the percentage of the variability in effect estimates due to heterogeneity rather than sampling error]. To be more conservative, we considered that heterogeneity was present when the Cochran's *Q* test *P* value was < 0.1 . In addition, inconsistency across studies was quantified by means of *I*² statistic, which is generally considered significant (i.e., heterogeneity has a significant effect on meta-analysis) for values $\geq 50\%$. In case of heterogeneity, meta-analysis was done by applying the random-effects model (6), which assumes that studies were a random sample of a hypothetical population of studies and assigns a weight to each study taking into account variance within and between studies.

The extent to which the combined risk estimate might be affected by individual studies was assessed by consecutively omitting every study from the meta-analysis. Subgroup analysis considering more homogeneous sets of studies was adopted as an additional sensitivity test. Furthermore, to identify potential sources of heterogeneity, random-effects meta-regression was also implemented, as per Thompson and Sharp (7). In brief, potential explanatory (independent) variables (covariates, i.e., study features that might affect the magnitude of the effect estimate) were regressed against the outcome (dependent) variable (lnHR), after that each study was weighted by the precision of its respective effect estimate ($1 / \text{SE}[\ln HR]$). Residual heterogeneity (not explained by the covariates) was incorporated in the weight formula ($1 / [\text{SE} + \tau^2]$) by allowing an additive between-study variance component τ^2 , which was estimated according to the following formula:

$$\tau^2 = [Q - (k - 2)] / F(w, x)$$

where *Q* is the heterogeneity statistic, *k* is the number of studies, *w* is the estimate precision, *x* is the covariate, and

$$F(w, x) = \sum w - \frac{\sum w^2 \sum wx^2 - 2 \sum w^2 x \sum wx + \sum w \sum w^2 x^2}{\sum w \sum wx^2 - (\sum wx)^2}$$

Publication bias (linked to the fact that negative trials are cited less frequently and are therefore more likely to be missed in the search for relevant studies) was sought with the "funnel plot" technique (based on a graph plotting effect estimates against sample size; ref. 8). Funnel plot asymmetry on the natural logarithm scale of the HR was formally investigated with Egger's method, a linear regression approach in which the standard normal deviate (the HR divided by its SE) is regressed against the estimate precision ($1/\text{SE}$; ref. 9). The effect of publication bias on the pooled effect was assessed by the "trim-and-fill" method described by Duval and Tweedie (10), using both *L*₀ and *R*₀ as estimators of the potentially missing studies; to this aim the following formulas were used:

$$L_0 = \frac{4T_n - n(n + 1)}{2n - 1}$$

and

$$R_0 = \gamma^* - 1,$$

where *n* is the number of published studies and *T_n* is the "trimmed" rank test statistic.

Study quality was quantitatively assessed by comparing the number of patients enrolled in each study with the estimated minimum number of cases needed to reach a statistical power of 80% with a type α error

<5%. When considering the association between CTC status and TNM stage, the expected sample sizes were estimated under the following assumptions: (a) equal sample size of stage populations and (b) expected CTC positivity rates equivalent to the 5-year mortality rate per stage (10%, 33%, 55%, and 90% for stage I, II, III, and IV, respectively; ref. 11).

Sample sizes for survival analysis were estimated under the following assumptions: (a) equal sample size of stage populations; (b) expected CTC positivity rates equivalent to the 5-year mortality rate per stage; (c) HR, 2; and (d) median PFS, 50% of median OS.

Meta-analysis was conducted using the RevMan software version 4.2 (The Cochrane Collaboration, Oxford, United Kingdom). Other statistical analyses were done in the "R" environment (release version 2.2.0) and using the SPSS statistical package (SPSS, Inc., Chicago, IL, release version 13.0). Values of 95% CI were used for all analyses. Probability values <5% were considered significant.

Results

Characteristics of identified studies

Literature search with the above-mentioned keywords yielded 209 articles; of these, 123 articles reporting on CTC detection in melanoma patients were reviewed in detail (Fig. 1). Excluding reviews and those reporting only on methodologic aspects, 53 original articles met all inclusion criteria and represent the source of the data analyzed here (12–64). A list of excluded articles is reported in Supplementary Table S2.

The included 53 studies encompassed 5,433 patients affected with TNM stage I to IV cutaneous ($n = 5,388$; 99.2%) and uveal ($n = 45$; 0.8%) melanoma. The mean number of patients enrolled was 102 (range 30–299), with 20 (37.7%) and 6 (11.3%) studies enrolling ≥ 100 and 200 patients, respectively. Considering the studies that reported patient demographics (36 of 53, 67.9%), there were 1,823 females (49.6%) and 1,854 males (50.4%), and the mean age was 51.6 years (range 36–57 years).

In 47 studies (88.7%) 1,361 controls (healthy persons or patients with cancers other than melanoma) were enrolled (mean 29, range 1–89).

All TNM stages (I–IV) were considered in 31 studies (58.5%); stage I, II, and III were considered in seven (13.2%), eight

(15.1%), and seven (13.2%) studies, respectively. Overall, stage IV patients were enrolled in most series (41 of 53, 77.3%).

Spiking experiments to test *in vitro* the sensitivity of CTC detection methods were reported in 43 of 53 studies (81.1%). In 30 studies (69.8%), it was possible to find one melanoma cell in 1×10^6 peripheral blood mononuclear cells or in 5 mL whole blood; in the other 13, the sensitivity was lower.

The mean blood sample volume was 10.7 mL (range 1–50 mL), with 35 of 51 evaluable studies using ≥ 10 mL (68.6%). Single and multiple blood withdrawals per patient were done in 28 (52.8%) and 25 (47.2%) studies, respectively. Considering 52 evaluable studies, CTC were searched in peripheral blood samples after density gradient cell separation and RBC lysis in 26 (50%) and 7 cases (13.4%), respectively, whereas whole blood was used in 17 (32.7%); a miscellany of these approaches was adopted in two studies (3.9%). CTC detection was based on PCR in all but one study, in which the authors used immunomagnetic cell enrichment combined with light microscopy (56). Among PCR-based methods, nested PCR was the most widely used (42 of 52, 80.7%). Single-round PCR was used in six cases (11.5%), quantitative real-time PCR in three (5.8%), and a mix of single and nested PCR in one (2%). PCR was enhanced with Southern blot, ELISA, and electrochemoluminescence analysis of amplicons in nine (17.3%), two (3.8%), and one (1.9%) study, respectively.

CTC identification hinged upon single and multiple (mean 2.9, range 2–5) tumor markers in 30 (56.6%) and 23 (43.4%) cases, respectively. In the only study using the cytometric approach (which hinges upon visualization of intact CTC, as opposed to PCR-based methods where normal peripheral blood mononuclear cell and potentially contaminating CTC are lysed to extract the genetic material and assess the expression of tumor-related genes), immunomagnetic cell enrichment was based on a monoclonal antibody directed to melanoma-associated chondroitin sulfate proteoglycan, and light microscopy was used to recognize circulating melanoma cells by morphology only. In the other studies, PCR was directed to amplify genes coding for nine different melanoma-associated markers: tyrosinase (49 of 52 studies; 94.2%), melanoma antigen recognized by T cells-1 (MART1/Melan-A; 19 of 52, 36.5%), melanoma antigen gene family (7 of 52, 13.5%), glycoprotein gp100/pmel17 (5 of 52, 9.6%), melanotransferrin (p97; 3/52, 5.8%), tyrosinase-related proteins (3 of 52, 5.8%), β -N-acetyl-galactosaminyl-transferase (3 of 52, 5.8%), melanoma cell adhesion molecule MUC18 (2 of 52, 3.8%), paired box homeotic gene transcription factor-3 (2 of 52; 3.8%), and melanoma inhibitory activity protein (1 of 52, 1.9%).

Effect of study design variables on CTC detection

Data regarding CTC positivity rates were extracted according to the following rules: When the expression of more than one tumor marker per sample was assessed and/or more than one blood sample per patient was withdrawn, we considered positive a case positive to at least one marker in at least one sample. If these data were unavailable, either the marker with the best specificity (lowest false-positive rates among controls) or the one correlating with stage or survival was chosen. Similarly, the sample series (e.g., before versus after treatment) correlating with stage/survival was chosen. Whenever possible, we evaluated per patient (not per sample) results.




Fig. 1. Methodologic flow chart of the systematic review.




Fig. 2. Quality of studies included in the systematic review. Gray areas of columns, percentage of studies reporting each single variable or enrolling a number of patients greater than or equal to the sample size calculated according to the assumptions described in the text. White areas of columns, number of studies not reporting the data or not reaching the expected sample size.

Considering that in five studies results were reported (partially or systematically) on a per sample basis (13, 24, 26, 30, 54), CTC were detected in 2,231 of 5,644 cases (39.5%) and in 8 of 1,361 controls (false-positive rate, 0.6%). The latter value might be underestimated, as controls were sampled once in virtually all studies, whereas patients were sampled multiple times in 25 of 53 series.

To investigate whether study design or technical features might influence CTC detection, nine independent variables were analyzed: publication year, *in vitro* sensitivity (one versus more melanoma cells per 1×10^6 peripheral blood mononuclear cells or per 5 mL peripheral blood), number of TNM stages considered (one to four), inclusion of stage IV patients (yes versus no), sample volume (milliliters), number of samples (single versus multiple), number of tumor markers (single versus multiple), type of PCR (nested versus other), and type of blood manipulation (density gradient cell separation versus other). Considering all 53 studies, after stepwise model variable selection and case-wise deletion of missing values, only the number of markers significantly and independently affected CTC positivity rates, the use of multiple markers being correlated with higher CTC detection rates (odds ratio, 2.14; 95% CI, 1.1-4.16; P : 0.025).

CTC prognostic value

Correlation with disease stage. Among the 5,433 enrolled patients, 9 will not be considered in the following TNM stage-related analysis because they were in stage 0 (*in situ* melanoma; ref. 49): these patients, however, will be considered in the following paragraph regarding survival analysis, as the authors included them in the Cox model. In older publications where a three-stage classification was adopted, stage I, II, and III have been considered to correspond to currently accepted stage I-II, III, and IV, respectively. Therefore, of 5,424 patients, 984 were in stage I (18.1%), 329 in stage I-II (6.0%), 1,022 in stage II (18.8%), 356 in stage II-III (6.6%), 1,376 in stage III (25.4%), 126 in stage III-IV (2.3%), 46 in stage II-IV (0.8%), and 1,185 in stage IV (21.8%).

Taking into consideration 46 studies ($n = 4,974$) reporting on two or more TNM stages, the number of patients enrolled was lower than that expected for trend test analysis only in

seven studies (refs. 28, 29, 33, 45, 55, 61, 64; Fig. 2; Supplementary Fig. S1). The correlation between CTC detection and TNM stage was evaluated by combining the data of each single stage across series, which was possible in 46 of 53 studies (86.8%). Taking into account that CTC positivity was expressed on a per sample basis (or as a mixture of patients and samples) in five series (13, 24, 26, 30, 54), CTC positivity rates were 32% (319 of 995; 95% CI, 29.1-35.0%) in stage I, 41.7% (413 of 989; 95% CI, 38.6-44.9%) in stage II, 41.1% (582/1,414; 95% CI, 38.5-43.7%) in stage III, and 47.4% (597 of 1,258; 95% CI, 44.6-50.2%) in stage IV. The Cochran-Armitage test revealed a significant linear trend for CTC positivity among the four stages ($P < 0.0001$), although the association seems to be linked mostly to the difference between the extreme stages (I and IV). However, CTC detection rates were remarkably similar across TNM stages (range 32-47.4%) and significantly different from those one would expect based on the survival rates observed in patients with different stages of disease (Fig. 3; ref. 11).

Correlation with survival. The studies correlating CTC status with death or relapse rates by means of χ^2 statistics (13, 23, 27, 28, 31, 39, 60) were not considered in the following analysis, but the results are reported in Supplementary Table S1.

Survival analysis according to CTC status was done in 22 of 53 studies (41.5%) encompassing 2,401 patients (2,401 of 5,433: 44.2%; refs. 14, 15, 22, 25, 29, 34, 36, 37, 41, 45, 46, 48-50, 53, 55-58, 62-64). The mean follow-up was 35.4 months (range 9-75 months). Patient distribution by stage was as follows: stage 0: 9 (0.4%); stage I: 403 (16.8%); stage I-II: 16 (0.7%); stage II: 528 (22%); stage II-III: 356 (14.8%); stage III: 628 (26.1%); stage II-IV: 46 (1.9%); stage IV: 415 (17.3%). OS and PFS survival was analyzed in 13 (1,078 patients; refs. 14, 22, 29, 36, 37, 41, 45, 53, 56-58, 62, 64) and 16 (1,962 patients; refs. 15, 25, 29, 34, 36, 45, 46, 48-50, 53, 55, 57, 58, 63, 64) studies, respectively; in seven series (29, 36, 45, 53, 57, 58, 64), the authors analyzed both OS and PFS.

As regards OS, no study reported the estimated sample size and 3 of 13 (23%; refs. 36, 37, 62) reached the required sample size calculated under the assumptions described above (Fig. 2; Supplementary Fig. S2).




Fig. 3. CTC positivity rates observed in 3,667 patients with TNM stage I to IV melanoma compared with the 5-year mortality rates.




Fig. 4. Forest plot of HRs for overall survival from 13 studies (1,078 patients). M, multivariate analysis (Cox proportional hazard model); U, univariate analysis (log-rank test).

Univariate analysis alone (log-rank based comparison of Kaplan-Meier curves) was done in 4 of 13 studies (30.8%; refs. 14, 29, 37, 41). Multivariate analysis (Cox proportional hazards model) was done in the remaining nine series (69.2%; refs. 22, 36, 45, 53, 56–58, 62, 64). In one study (45), the authors stated that CTC status was not an independent predictor of OS, but the statistic necessary for meta-analysis (HR, CI) was not reported; therefore, in this case, we extracted the survival data from the Kaplan-Meier curve.

Singularly taken, 11 of 13 series (84.6%) reported a significant correlation between OS and CTC status (three at univariate and eight at multivariate analysis, respectively). In contrast, two studies (15.4%; refs. 41, 45) showed negative results (at univariate and multivariate analysis, respectively). Of note, these negative results come from studies underpowered for type- β error (power ≈ 0.3).

Meta-analysis (Fig. 4) of pooled data showed a significantly increased risk of death in patients with CTC positivity (HR, 2.42; 95% CI, 1.7–3.45; $P < 0.0001$). Because heterogeneity tests were positive (Q statistic $P = 0.001$; $I^2 = 63.5\%$), the random-effects model was applied to estimate the overall effect. The results of subgroup analysis, including eight studies reporting the statistic of the multivariate Cox model, were similar to these findings (HR, 3.02; 95% CI, 1.92–4.75; $P < 0.0001$), suggesting that the type of statistic (univariate versus multivariate) had no remarkable effect on the outcome of the analysis. Moreover, the “leave-one-out” procedure revealed that no single study accounted for heterogeneity.

While performing meta-regression, we considered the following covariates as potential sources of heterogeneity: year of publication, sample size, number of stages (one to four), stage

IV inclusion, type of PCR (nested versus other), type of blood manipulation (density gradient cell separation versus other), blood sample volume (milliliters), number of blood samples per patient (single versus multiple), number of tumor markers used (single versus multiple), and CTC positivity rate. Meta-regression did not identify any covariate significantly associated with HR estimates; however, because this analysis was characterized by a low power, we cannot rule out that with larger sample sizes one or more of the covariates we considered might significantly affect the meta-analysis outcome.

The weights of the studies (mean 7.7%, SE 0.66) were not statistically different from the expected average weight (one-sample t test $P = 0.99$). The lack of a dominant study leading the results of meta-analysis was confirmed by the leave-one-out procedure, which generated HR estimates (mean HR, 2.45; range 2.19–2.62) very close to those obtained with all 13 studies.

The Egger’s test (intercept -0.34 ; $P = 0.002$) showed funnel plot asymmetry, which suggested publication bias. Applying the trim-and-fill procedure, three studies were estimated to be missing, and the adjusted estimate of overall HR resulted 1.74 (95% CI, 1.44–2.11, $P < 0.0001$).

Considering PFS, no study reported the estimated sample size and seven (46.7%; refs. 25, 36, 46, 48–50, 57) reached the required sample size calculated on the basis of the conditions made for the above described assumption (Fig. 2; Supplementary Fig. S2).

Univariate analysis alone was done in 2 of 15 studies (13.3%; refs. 29, 46). Multivariate analysis based on the Cox model was done in the remaining 13 cases (86.7%; refs. 25, 34, 36, 45, 48–50, 53, 55, 57, 58, 63, 64).

In one study (15), the authors stated that CTC status was an independent predictor of OS; however, they did not report the statistic necessary for meta-analysis (HR, CI). Therefore, we did not include this series in the following meta-analysis also in the light of the fact that a partially overlapping series published later by the same group (29) is included in the following analysis.

Singularly taken, 11 of 15 series (73.3%) reported a significant correlation between PFS and CTC status; in contrast, four studies (26.7%; refs. 46, 49, 57, 63) showed negative results (three at multivariate and one at univariate analysis; ref. 46). For one of them, the study power was ≈ 0.5 (63). In another study enrolling stage 0 to IV patients (49), on the exclusion of stage IV cases, the multivariate analysis showed that CTC detection was independently associated with a worse prognosis.

Our meta-analysis (Fig. 5) confirmed a significantly increased risk of disease progression in patients with CTC positivity (HR, 2.45; 95% CI, 1.78-3.38; $P < 0.0001$).

Because heterogeneity was significant (Q statistic $P = 0.0001$; $I^2 = 66.7\%$), the random-effects model was applied to estimate the overall effect. The results of subgroup analysis, including 13 studies reporting the statistic of the multivariate Cox model, were similar to these findings (HR, 2.56; 95% CI, 1.96-3.34; $P < 0.0001$), suggesting that the type of survival statistic had no remarkable effect on the outcome variable. According to the leave-one-out procedure, no single study accounted for heterogeneity.

Considering the same covariates analyzed for OS, meta-regression did not identify potential sources of heterogeneity.

The weights of the studies (mean 6.6%, SE 0.56) were not statistically different from the expected average weight (one-sample t test $P = 0.94$). The lack of a dominant study was confirmed by the leave-one-out procedure, which generated HR estimates very close to those obtained with all 15 studies (mean HR 2.43; range 2.33-2.62).

Egger's test suggested that publication bias was present (intercept -1.29 ; $P < 0.0001$). The trim-and-fill analysis revealed that one study might be missing and that if this were published, the adjusted HR would be 2.34 (95% CI, 1.71-3.21; $P < 0.0001$).

Discussion

Current prognostic systems (e.g., TNM staging system, primary tumor molecular features, and serum biomarkers) are largely inadequate for an optimal therapeutic management of melanoma patients, as shown by the fact that many patients radically treated (i.e., without evidence of residual disease according to conventional methods) do experience disease recurrence, whereas others currently considered eligible for, and treated with, adjuvant therapy do not require it, as they will not recur (e.g., $\sim 50\%$ of patients with TNM stage III melanoma; ref. 11). Detection of CTC might represent an ideal prognostic tool as the presence of malignant cells in the peripheral blood is a necessary (although not sufficient) phenomenon for the development of metastatic tumor spread. Unfortunately, there is no consensus on whether CTC detection has a prognostic power reliable enough to be implemented in the routine clinical practice.




Fig. 5. Forest plot of HRs for PFS from 15 studies (1,871 patients). M, multivariate analysis (Cox proportional hazard model); U, univariate analysis (log-rank test).

The present analysis is based on a large pool of clinical series ($n = 5,433$ patients) and substantially differs from the other two meta-analyses thus far published (65, 66), which considered smaller series (1,799 and 861 patients, respectively), evaluated studies analyzing only one melanoma marker (tyrosinase), and addressed the correlation of CTC status with TNM stage, but not with survival.

Overall, our results support the hypothesis that CTC could play a clinically useful prognostic role in patients with melanoma. In fact, most studies reported a significant correlation between CTC detection and patients' survival, and most of them showed CTC-independent prognostic value at multivariate analysis. In addition, meta-analysis of pooled data confirmed that CTC represent a significant meta-risk for both OS and PFS, even after adjustment for publication bias. Nevertheless, our findings also hint some considerations that suggest caution in interpreting this favorable outcome and, on the other hand, might pave the way to the design of more informative studies.

The significant heterogeneity found in the meta-analysis for both OS and PFS is likely to be sustained by the number of differences existing between studies, such as stage of disease (from one to four), timing of blood withdrawal (before versus during versus after treatment; with versus without evidence of disease), methods of CTC detection (PCR-based versus cytometric), technical features (density gradient cell separation versus RBC lysis versus whole blood; with versus without cell enrichment; different PCR primers for the same marker; different PCR and cytometry methods), type and number of tumor markers analyzed, definition of risk (CTC presence/absence versus CTC cutoff values; refs. 34, 56, 58), clinical end point (correlation with disease stage or survival), and statistical analysis (univariate versus multivariate survival analysis, different covariates investigated at multivariate analysis). Moreover, intrastudy variability (e.g., enrollment of patients treated with different regimens or blood samples withdrawn at different time points of the patients' treatment schedule) made it virtually impossible to assess the effect of one of the most important variables (concomitant treatment) potentially affecting CTC detection. Although at meta-regression, no covariate significantly correlated with HR estimates, the analysis was not characterized by an adequate type- β error, which does not allow us to rule out that one or more covariates do represent a source of heterogeneity. As a corollary, these considerations should prompt investigators to validate the prognostic power of CTC by studying large homogeneous series of patients enrolled in multicenter prospective studies adopting standardized technical protocols.

The favorable results regarding survival analysis are at least in part conflicting with the observed CTC positivity rates per stage. The remarkable discrepancy between the CTC detection rates (32-41.7%) and the expected 5-year mortality rates (~ 10 -33%) in patients with early stage melanoma (stage I, II) suggests that the false-positive rate might be an important hurdle to be tackled to definitely show CTC prognostic value. With regard to PCR-based methods, contamination events, amplification of

pseudogenes, and illegitimate transcription can lead to false-positive results. Quantitative methods (both PCR-based and cytometric) can be used to set cutoff values distinguishing illegitimate transcription from marker expression by CTC (54). Furthermore, a broader implementation of cytometric methods, which allow for a morphologic identification of intact CTC, could significantly minimize the issue of false positivity associated with PCR-based methods.

Besides technical issues, the substantially unknown biology of CTC might contribute to the false-positive rate. In particular, the phenomenon of metastatic inefficiency can undermine the prognostic power of a strategy simply based on the presence/absence of CTC.

Some investigators (34, 56, 58) proposed the use of a cutoff to distinguish low-load from high-load CTC detection, which should distinguish low-risk from high-risk patients. To further increase the specificity of CTC detection assay meant as a prognostic tool, another approach is based on the use of target genes/proteins involved in cancer cell survival and biological aggressiveness, which is not the case for virtually all tumor markers thus far used.

On the opposite side, the CTC detection rate observed in stage IV patients (47.4%) is lower than expected (~ 80 -90%), indicating that currently used detection systems are not sufficiently sensitive. Poor quality source material might lead to false-negative results. In effect, quality control has not been clearly mentioned in many publications: by contrast, only rigid per sample controls (e.g., sample quality assessment by quantitation of housekeeping gene expression) can provide reliable and comparable results. Moreover, the fact that most patients with metastatic disease are on treatment can have profound effects on CTC detection and prognostic value (27, 35, 48, 50, 57, 58). Finally, intermittent shedding of CTC into the bloodstream and genomic instability of malignant cells can also lead to false-negative results. A logical way to deal with these issues is to obtain multiple samples from each patient and to analyze the expression of multiple markers, respectively, to increase the likelihood of detecting CTC. However, in our analysis, only the use of multiple markers was associated with higher CTC detection rates.

In conclusion, although thousands of patients with melanoma have been enrolled over the last decade, available evidence is not sufficient to conclude that circulating melanoma cells are a biomarker reliable enough to be clinically implemented in the therapeutic decision-making process. However, the results of the present work justify researchers and clinicians to further investigate the prognostic power of CTC that can only be definitely validated (or confuted) by dissecting the molecular biology of CTC and by conducting large multicenter prospective studies based on homogeneous series of patients and designed according to standardized protocols.

Acknowledgments

We thank Salvatore Correrà for his technical help with the literature search.

References

- Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells, the "leukemic phase" of solid tumors: does it matter? *Trends Mol Med* 2006;12:130-9.
- Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. *Lancet* 1991;338:1227-9.
- Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. Chichester: Wiley; 2000.
- Alderson P, Green S, Higgins JPT. Cochrane reviewers' handbook 4.2.2. Chichester: Wiley; 2004.

5. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Stat Med* 1998;17:2815–34.
6. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177–88.
7. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. *Stat Med* 1999;18:2693–708.
8. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. *Lancet* 1991;337:867–72.
9. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
10. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56:455–63.
11. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. *J Clin Oncol* 2001;19:3622–34.
12. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Mohler T, Hunstein W. Hematogenous spread of malignant melanoma cells in different stages of disease. *J Invest Dermatol* 1993;101:887–9.
13. Battayani Z, Grob JJ, Xerri L, et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. *Arch Dermatol* 1995;131:443–7.
14. Kunter U, Buer J, Probst M, et al. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. *J Natl Cancer Inst* 1996;88:590–4.
15. Mellado B, Colomer D, Castel T, et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. *J Clin Oncol* 1996;14:2091–7.
16. Glaser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. *J Clin Oncol* 1997;15:2818–25.
17. Jung FA, Buzaid AC, Ross MI, et al. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. *J Clin Oncol* 1997;15:2826–31.
18. Reinhold U, Ludtke-Handjery HC, Schnautz S, Kreysel HW, Abken H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. *J Invest Dermatol* 1997;108:166–9.
19. Sarantou T, Chi DD, Garrison DA, et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. *Cancer Res* 1997;57:1371–6.
20. Tessier MH, Denis MG, Lustenberger P, Dreno B. Detection of circulating neoplastic cells by reverse transcriptase and polymerase chain reaction in melanoma. *Ann Dermatol Venereol* 1997;124:607–11.
21. Farthmann B, Eberle J, Krasagakis K, et al. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. *J Invest Dermatol* 1998;110:263–7.
22. Ghossein RA, Coit D, Brennan M, et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. *Clin Cancer Res* 1998;4:419–28.
23. Kuo CT, Bostick PJ, Irie RF, Morton DL, Conrad AJ, Hoon DS. Assessment of messenger RNA of β 1–4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma. *Clin Cancer Res* 1998;4:411–8.
24. Berking C, Schlupen EM, Schrader A, Atzpodien J, Volkenandt M. Tumor markers in peripheral blood of patients with malignant melanoma: multimarker RT-PCR versus a luminoimmunometric assay for S-100. *Arch Dermatol Res* 1999;291:479–84.
25. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. *J Clin Oncol* 1999;17:2562–71.
26. deVries TJ, Fourkour A, Punt CJ, et al. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR. *Br J Cancer* 1999;80:883–91.
27. Hanekom GS, Stubbings HM, Johnson CA, Kidson SH. The detection of circulating melanoma cells correlates with tumour thickness and ulceration but is not predictive of metastasis for patients with primary melanoma. *Melanoma Res* 1999;9:465–73.
28. Le Bricon T, Stoitchkov K, Letellier S, et al. Simultaneous analysis of tyrosinase mRNA and markers of tyrosinase activity in the blood of patients with metastatic melanoma. *Clin Chim Acta* 1999;282:101–13.
29. Mellado B, Gutierrez L, Castel T, et al. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. *Clin Cancer Res* 1999;5:1843–8.
30. Muhlbauer M, Langenbach N, Stolz W, et al. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR. *Clin Cancer Res* 1999;5:1099–105.
31. Schitteck B, Bodingbauer Y, Ellwanger U, Blaheta HJ, Garbe C. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. *Br J Dermatol* 1999;141:30–6.
32. Aubin F, Chtourou M, Teysier JR, et al. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. *Melanoma Res* 2000;10:113–8.
33. Baldi A, Dragonetti E, Battista T, et al. Detection of circulating malignant cells by RT-PCR in long-term clinically disease-free I stage melanoma patients. *Anticancer Res* 2000;20:3923–8.
34. Hoon DS, Bostick P, Kuo C, et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. *Cancer Res* 2000;60:2253–7.
35. Osella Abate S, Savoia P, Cambieri I, Salomone B, Quaglino P, Bernengo MG. Role of RT-PCR tyrosinase detection in the monitoring of patients with advanced metastatic melanoma. *Melanoma Res* 2000;10:545–55.
36. Proebstle TM, Jiang W, Hogel J, Keilholz U, Weber L, Voit C. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. *Br J Cancer* 2000;82:118–23.
37. Schrader AJ, Probst-Kepper M, Grosse J, et al. Tumour microdissemination and survival in metastatic melanoma. *Anticancer Res* 2000;20:3619–24.
38. Tsukamoto K, Ueda M, Hirata S, et al. gp100 mRNA is more sensitive than tyrosinase mRNA for RT-PCR amplification to detect circulating melanoma cells in peripheral blood of melanoma patients. *J Dermatol Sci* 2000;23:126–31.
39. Brownbridge GG, Gold J, Edward M, MacKie RM. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled-polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. *Br J Dermatol* 2001;144:279–87.
40. Kulik J, Nowecki ZI, Rutkowski P, et al. Detection of circulating melanoma cells in peripheral blood by a two-marker RT-PCR assay. *Melanoma Res* 2001;11:65–73.
41. Quereux G, Denis M, Khammari A, Lustenberger P, Dreno B. Prognostic value of tyrosinase reverse-transcriptase polymerase chain reaction in metastatic melanoma. *Dermatology* 2001;203:221–5.
42. Reinhold U, Berkin C, Bosserhoff AK, et al. Interlaboratory evaluation of a new reverse transcriptase-polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: a multicenter study of the Dermatologic Cooperative Oncology Group. *J Clin Oncol* 2001;19:1723–7.
43. Strohal R, Mosser R, Kittler H, et al. MART-1/Melan-A and tyrosinase transcripts in peripheral blood of melanoma patients: PCR analyses and follow-up testing in relation to clinical stage and disease progression. *Melanoma Res* 2001;11:543–8.
44. Carrillo E, Prados J, Melguizo C, et al. Reverse transcriptase-polymerase chain reaction detection of circulating tumor cells in patients with melanoma: correlation with clinical stage, tumor thickness and histological type. *Pathol Int* 2002;52:294–9.
45. Gogas H, Kefala G, Bafaloukos D, et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. *Br J Cancer* 2002;87:181–6.
46. Garbe C, Leiter U, Ellwanger U, et al. Diagnostic value and prognostic significance of protein S-100 β , melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. *Cancer* 2003;97:1737–45.
47. Jin HY, Yamashita T, Minamitsuji Y, Omori F, Jimbow K. Detection of tyrosinase and tyrosinase-related protein 1 sequences from peripheral blood of melanoma patients using reverse transcription-polymerase chain reaction. *J Dermatol Sci* 2003;33:169–76.
48. Osella-Abate S, Savoia P, Quaglino P, et al. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. *Br J Cancer* 2003;89:1457–62.
49. Palmieri G, Ascierto PA, Perrone F, et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. *J Clin Oncol* 2003;21:767–73.
50. Reynolds SR, Albrecht J, Shapiro RL, et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. *Clin Cancer Res* 2003;9:1497–502.
51. Szenajch J, Jasinski B, Synowiec A, et al. Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma. *Clin Chem* 2003;49:1450–7.
52. Warr RP, Zebedee Z, Kenealy J, Rigby H, Kemshead JT. The detection of tyrosinase mRNA in peripheral blood samples is unlikely to aid in the management of patients with localised malignant melanoma. *Br J Plast Surg* 2003;56:540–5.
53. Wascher RA, Morton DL, Kuo C, et al. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. *J Clin Oncol* 2003;21:2558–63.
54. Keilholz U, Goldin-Lang P, Bechrakis NE, et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. *Clin Cancer Res* 2004;10:1605–12.
55. Mocellin S, Del Fiore P, Guarnieri L, et al. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. *Int J Cancer* 2004;111:741–5.
56. Ulmer A, Schmidt-Kittler O, Fischer J, et al. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. *Clin Cancer Res* 2004;10:531–7.
57. Domingo-Domenech J, Molina R, Castel T, et al. Serum protein S-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon-combination with tyrosinase rt-PCR. *Oncology* 2005;68:341–9.
58. Koyanagi K, O'Day SJ, Gonzalez R, et al. Serial monitoring of circulating melanoma cells during

- neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. *J Clin Oncol* 2005;23:8057–64.
59. Koyanagi K, Kuo C, Nakagawa T, et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. *Clin Chem* 2005;51:981–8.
60. Ranieri JM, Wagner JD, Wiebke EA, et al. Lack of prognostic importance of reverse-transcriptase polymerase chain reaction detection of circulating messenger RNA in patients with melanoma. *Plast Reconstr Surg* 2005;115:1058–63.
61. Santonocito C, Concolino P, Lavieri MM, et al. Comparison between three molecular methods for detection of blood melanoma tyrosinase mRNA. Correlation with melanoma stages and S100B, LDH, NSE biochemical markers. *Clin Chim Acta* 2005;362:85–93.
62. Schmidt H, Sorensen BS, Fode K, Nexø E, von der Maase H. Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. *Melanoma Res* 2005;15:409–16.
63. Schmidt H, Sorensen BS, Sjoegren P, et al. Circulating tyrosinase and MART-1 messenger RNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma. *J Invest Dermatol* 2005;126:849–54.
64. Voit C, Kron M, Rademaker J, et al. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. *J Clin Oncol* 2005;23:1218–27.
65. Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. *Arch Dermatol* 2001;137:325–30.
66. Quaglino P, Savoia P, Fierro MT, Osella-Abate S, Bernengo MG. Clinical significance of sequential tyrosinase expression in the peripheral blood of disease-free melanoma patients: a review of literature data. *Melanoma Res* 2004;14:S17–9.